These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 101569)

  • 21. Costs and benefits of cervical screening. II. Is it worthwhile reducing the screening interval from 5 to 3 years?
    Waugh N; Robertson A
    Cytopathology; 1996 Aug; 7(4):241-8. PubMed ID: 8853970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
    Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
    Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-benefit analysis of a national thalassaemia prevention programme in Israel.
    Ginsberg G; Tulchinsky T; Filon D; Goldfarb A; Abramov L; Rachmilevitz EA
    J Med Screen; 1998; 5(3):120-6. PubMed ID: 9795870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current practice, accuracy, effectiveness and cost-effectiveness of the school entry hearing screen.
    Bamford J; Fortnum H; Bristow K; Smith J; Vamvakas G; Davies L; Taylor R; Watkin P; Fonseca S; Davis A; Hind S
    Health Technol Assess; 2007 Aug; 11(32):1-168, iii-iv. PubMed ID: 17683682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.
    Hobbs FD; Fitzmaurice DA; Mant J; Murray E; Jowett S; Bryan S; Raftery J; Davies M; Lip G
    Health Technol Assess; 2005 Oct; 9(40):iii-iv, ix-x, 1-74. PubMed ID: 16202350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost of quality management and information provision for screening: colorectal cancer screening.
    Robert G; Brown J; Garvican L
    J Med Screen; 2000; 7(1):31-4. PubMed ID: 10807144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs and benefits of cervical screening. III. Cost/benefit analysis of a call of previously unscreened women.
    Waugh N; Smith I; Robertson A; Reid GS; Halkerston R; Grant A
    Cytopathology; 1996 Aug; 7(4):249-55. PubMed ID: 8853971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of a domestic violence and abuse training and support programme in primary care in the real world: updated modelling based on an MRC phase IV observational pragmatic implementation study.
    Barbosa EC; Verhoef TI; Morris S; Solmi F; Johnson M; Sohal A; El-Shogri F; Dowrick S; Ronalds C; Griffiths C; Eldridge S; Lewis NV; Devine A; Spencer A; Feder G
    BMJ Open; 2018 Aug; 8(8):e021256. PubMed ID: 30158224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for hypertension.
    Littenberg B; Garber AM; Sox HC
    Ann Intern Med; 1990 Feb; 112(3):192-202. PubMed ID: 2136982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of molecular techniques in prediction and diagnosis of cytomegalovirus disease in immunocompromised patients.
    Szczepura A; Westmoreland D; Vinogradova Y; Fox J; Clark M
    Health Technol Assess; 2006 Apr; 10(10):1-176. PubMed ID: 16595079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India.
    Kumar M; Birch S; Maturana A; Gafni A
    Health Policy; 2006 Jul; 77(2):233-43. PubMed ID: 16126300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis.
    Macintyre CR; Plant AJ; Hendrie D
    Health Econ; 2000 Jul; 9(5):411-21. PubMed ID: 10903541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factor profile and achievement of treatment goals among hypertensive patients from the Israeli Blood Pressure Control (IBPC) program--initial cost utility analysis.
    Yosefy C; Ginsberg GM; Dicker D; Viskoper JR; Tulchinsky TH; Leibovitz E; Gavish D;
    Blood Press; 2003; 12(4):225-31. PubMed ID: 14596359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
    Dehmer SP; Maciosek MV; LaFrance AB; Flottemesch TJ
    Ann Fam Med; 2017 Jan; 15(1):23-36. PubMed ID: 28376458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening.
    Koleva-Kolarova RG; Daszczuk AM; de Jonge C; Abu Hantash MK; Zhan ZZ; Postema EJ; Feenstra TL; Pijnappel RM; Greuter MJW; de Bock GH
    Maturitas; 2018 Mar; 109():81-88. PubMed ID: 29452787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective cost-effectiveness analysis of screening mammography.
    Stout NK; Rosenberg MA; Trentham-Dietz A; Smith MA; Robinson SM; Fryback DG
    J Natl Cancer Inst; 2006 Jun; 98(11):774-82. PubMed ID: 16757702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions?
    Wang PE; Wang TT; Chiu YH; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S54-8. PubMed ID: 17227644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
    BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.